Buntanetap Market

“Buntanetap Market Size, Forecast, and Emerging Insight − 2032” report offers an in-depth analysis of both the market and emerging insights regarding Buntanetap for the treatment of Parkinson’s disease and Alzheimer’s disease in Japan. A detailed picture of the Buntanetap in Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the Buntanetap. The report provides insights about the mechanism of action, dosage, and administration, as well as research and development, including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments, including the Buntanetap market forecast analysis in Japan, SWOT, analysts’ views, a comprehensive overview of market competitors, and a brief about other emerging therapies.

Drug Summary

Buntanetap (previously known as ANVS401 or posiphen) is an orally bioavailable small molecule derived via a synthetic biochemical pathway. It is a translational inhibitor of neurotoxic aggregating proteins (TINAPs). Buntanetap, thus, offers a transformative and superior mechanism to treat neurodegenerative disorders. It is being developed for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions such as Alzheimer’s in Down syndrome. 

Annovis has received positive results of the pre-planned interim analysis conducted by an independent data analytics provider, for statistical power in its Alzheimer’s study. This means that the trial is powered for potential success.

Recently, Annovis announced that the Phase II/III study of buntanetap for mild-to-moderate Alzheimer’s has exceeded full enrollment and that it anticipates topline data by March of 2024, and intends to file NDA with the US FDA by 2026. Annovis also plans to design an 18-month disease-modifying Phase III study in the same early Alzheimer’s disease patient population. In addition, it also plans to conduct a short 6-month study in advanced AD patients during the second half of the 18-month disease-modifying Phase III study. Buntanetap is also being studied in a Phase III study in early PD patients.

Gain a deeper understanding of the Market with DelveInsight’s detailed report @ Alzheimer’s Disease Treatment Market Size

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the Buntanetap description, mechanism of action, dosage and administration, research and development activities in Parkinson’s disease and Alzheimer’s disease.
• Elaborated details on Buntanetap regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Buntanetap research and development activities in Parkinson’s disease and Alzheimer’s disease across Japan.
• The report also covers the patents information with expiry timeline around Buntanetap.
• The report contains forecasted sales of Buntanetap for Parkinson’s disease and Alzheimer’s disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson’s disease and Alzheimer’s disease.
• The report also features the SWOT analysis with analyst views for Buntanetap in Parkinson’s disease and Alzheimer’s disease.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Alzheimer’s Disease Prevalence

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Buntanetap Analytical Perspective by DelveInsight

• In-depth Buntanetap Market Assessment

This report provides a detailed market assessment of Buntanetap for Parkinson’s disease and Alzheimer’s disease in Japan. This segment of the report provides forecasted sales data from 2029 to 2032.

• Buntanetap Clinical Assessment

The report provides the clinical trials information of Buntanetap for Parkinson’s disease and Alzheimer’s disease covering trial interventions, trial conditions, trial status, start and completion dates.

Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Alzheimer’s Disease Treatment Drugs

Report Highlights  

• In the coming years, the market scenario for Parkinson’s disease and Alzheimer’s disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Buntanetap dominance.
• Other emerging products for Parkinson’s disease and Alzheimer’s disease are expected to give tough market competition to Buntanetap, and the launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of Buntanetap in Parkinson’s disease and Alzheimer’s disease.
• Our in-depth analysis of the forecasted sales data of Buntanetap from 2029 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Buntanetap in Parkinson’s disease and Alzheimer’s disease. 

Key Questions

• What is the product type, route of administration and mechanism of action of Buntanetap?
• What is the clinical trial status of the study related to Buntanetap in Parkinson’s disease and Alzheimer’s disease, and the study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Buntanetap development?
• What are the key designations that have been granted to Buntanetap for Parkinson’s disease and Alzheimer’s disease?
• What is the forecasted market scenario of Buntanetap for Parkinson’s disease and Alzheimer’s disease?
• What are the forecasted sales of Buntanetap in Japan?  
• What are the other emerging products available and how are these giving competition to Buntanetap for Parkinson’s disease and Alzheimer’s disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson’s disease and Alzheimer’s disease?